The
metabotropic glutamate receptor 5 (mGluR5) is a target for drug development and for imaging studies of the
glutamate system in neurological and
psychiatric disorders. [11C]
AZD9272 is a selective mGluR5 PET radioligand that is structurally different from hitherto applied mGluR5 radioligands. In the present investigation we compared the binding patterns of radiolabeled
AZD9272 and other mGluR5 radioligands in the non-human primate (NHP) brain. PET studies were undertaken using [11C]
AZD9272 and the commonly applied mGluR5 radioligand [11C]
ABP688. Autoradiography studies were performed in vitro using [3H]
AZD9272 and the standard mGluR5 radioligands [3H]M-MTEP and [3H]
ABP688 in NHP tissue. Competition binding studies were undertaken in vivo and in vitro using different mGluR5 selective compounds as inhibitors. In comparison to other mGluR5 radioligands radiolabeled
AZD9272 displayed a distinct regional distribution pattern with high binding in ventral striatum, midbrain, thalamus and cerebellum. While the binding of [11C]
AZD9272 was almost completely inhibited by the structurally unique mGluR5 compound
fenobam (2.0 mg/kg; 98% occupancy), it was only partially inhibited (46% and 20%, respectively) by the mGluR5 selective compounds
ABP688 and MTEP, at a dose (2.0 mg/kg) expected to saturate the mGluR5. Autoradiography studies using [3H]
AZD9272 confirmed a distinct pharmacologic profile characterized by preferential sensitivity to
fenobam. The distinctive binding in ventral striato-pallido-thalamic circuits and shared pharmacologic profile with the pro-psychotic compound
fenobam warrants further examination of [11C]
AZD9272 for potential application in psychiatric neuroimaging studies.